Alpa Laboratories LimitedQ1 FY27 Results & Financial Update
Alpa Laboratories Limited: Q1 FY27 consolidated results and company financials – revenue ₹23.93 Cr, PAT ₹0.98 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Alpa Laboratories price & chart
Market price₹51.87
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Alpa Laboratories Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Alpa Laboratories Limited reported its consolidated financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, through its official exchange disclosures.
During the quarter, the company registered revenue from operations of INR 23.93 crore alongside a total income of INR 29.70 crore, bolstered by other income.
Profit before tax (PBT) and profit after tax (PAT) both stood at INR 0.98 crore for the three-month period, reflecting positive bottom-line performance.
The net profit margin for Q1 FY27 came in at 4.10 percent, calculated on total consolidated income.
Basic earnings per share (EPS) for the quarter was reported at INR 0.49.
Financial charges for the period included finance costs of INR 0.11 crore and depreciation and amortisation expenses totaling INR 0.72 crore.
The company reported zero tax expense for the quarter under review.
Alpa Laboratories Limited reported its consolidated financial results for the first quarter of fiscal year 2027, covering the period ended 30 June 2026, showcasing total operational revenue of INR 23.93 crore.
01 · Business model
What does Alpa Laboratories do?
Alpa Laboratories Limited is engaged in the pharmaceutical business, manufacturing and supplying various pharmaceutical formulations, medicines, and allied health products from its facility located in Indore, Madhya Pradesh.
The company generates its primary operating revenue through the sale of pharmaceutical products while supplementing its top line with other operating and non-operating income streams.
Its operational model combines core pharmaceutical manufacturing with cost management across finance and depreciation components to determine final profitability.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹23.93 Cr |
| Total income | ₹29.70 Cr |
| Profit before tax | ₹0.98 Cr |
| Profit after tax | ₹0.98 Cr |
| EPS | ₹0.49 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 4.1% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 4.1% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹5.77 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations for Q1 FY27 stood at INR 23.93 crore, representing the primary stream of product sales.
Total income reached INR 29.70 crore, supported by other income of INR 5.77 crore during the quarter.
The company generated revenue from operations of INR 23.93 crore during the quarter ended 30 June 2026 through the sale of manufactured pharmaceutical formulations.
Non-operating streams contributed INR 5.77 crore to total income, elevating overall consolidated income to INR 29.70 crore for Q1 FY27.
What drove margins
PAT margin on total income was 4.10 percent, with PBT and PAT matching at INR 0.98 crore due to zero tax expense recorded for the period.
Depreciation and amortisation expenses were recorded at INR 0.72 crore, while finance costs stood at INR 0.11 crore.
Depreciation and amortisation charges of INR 0.72 crore exerted a steady downward pressure on operating earnings during the period.
Finance costs were maintained at a low level of INR 0.11 crore, supporting bottom-line retention.
04 · Reported developments
What changed operationally
The company maintained a positive net profit of INR 0.98 crore and positive basic EPS of INR 0.49 for Q1 FY27.
The company maintained positive profitability with a net profit of INR 0.98 crore for the quarter.
05 · Items worth noticing
The line items that can distort a quick read
The company reported zero tax expense for the quarter, aligning PBT and PAT at INR 0.98 crore.
06 · Key Q&A
The quarter, answered directly
What does Alpa Laboratories do?
Alpa Laboratories Limited is engaged in the pharmaceutical business, manufacturing and supplying various pharmaceutical formulations, medicines, and allied health products from its facility located in Indore, Madhya Pradesh.
What is the clearest takeaway from Q1 FY27?
Alpa Laboratories Limited reported its consolidated financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, through its official exchange disclosures.
What drove revenue or demand?
Revenue from operations for Q1 FY27 stood at INR 23.93 crore, representing the primary stream of product sales.
What mattered most for margins or profitability?
PAT margin on total income was 4.10 percent, with PBT and PAT matching at INR 0.98 crore due to zero tax expense recorded for the period.
What should the next disclosure help confirm?
Monitor upcoming quarterly financial disclosures to track revenue trends and operating margin movements.
07 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
08 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarter Filings: Monitor upcoming quarterly financial disclosures to track revenue trends and operating margin movements.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.